Johnson & Johnson logo

Johnson & Johnson (JNJ)

Market Closed
5 Dec, 20:00
NYSE NYSE
$
201. 93
-0.55
-0.27%
$
500.07B Market Cap
29.06 P/E Ratio
4.96% Div Yield
6,935,279 Volume
9.91 Eps
$ 202.48
Previous Close
Day Range
200.81 203.45
Year Range
140.68 207.81
Want to track JNJ and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 46 days
J&J to stop late-stage study of add-on depression drug

J&J to stop late-stage study of add-on depression drug

Johnson & Johnson said on Thursday it will discontinue a late-stage study of its add-on treatment for major depressive disorder due to insufficient efficacy in the target patient population.

Reuters | 9 months ago
Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term

Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 9 months ago
Buy Johnson & Johnson (JNJ) Stock for Higher Highs?

Buy Johnson & Johnson (JNJ) Stock for Higher Highs?

Amid recent market volatility, Johnson & Johnson (JNJ) stock hit new 52-week highs of nearly $170 on Tuesday.

Zacks | 9 months ago
Johnson & Johnson (JNJ) Presents at 45th Annual TD Cowen Healthcare Conference (Transcript)

Johnson & Johnson (JNJ) Presents at 45th Annual TD Cowen Healthcare Conference (Transcript)

Johnson & Johnson (NYSE:JNJ ) 45th Annual TD Cowen Healthcare Conference March 4, 2025 11:10 AM ET Company Participants Tim Schmid - Executive Vice President, Worldwide Chairman, MedTech Conference Call Participants Josh Jennings - TD Cowen Josh Jennings Good morning. We are moving down the medical device track even further on Day Two of the TD Cowen 45th Annual Healthcare Conference.

Seekingalpha | 9 months ago
Johnson & Johnson Just Paid Investors: Here's How Much They Got

Johnson & Johnson Just Paid Investors: Here's How Much They Got

Johnson & Johnson (NYSE: JNJ) is rewarding its shareholders once again with a quarterly dividend of $1.24, payable on Tuesday, March 4.

247wallst | 9 months ago
Why the Market Dipped But Johnson & Johnson (JNJ) Gained Today

Why the Market Dipped But Johnson & Johnson (JNJ) Gained Today

Johnson & Johnson (JNJ) reachead $167.28 at the closing of the latest trading day, reflecting a +1.37% change compared to its last close.

Zacks | 9 months ago
3 Top High-Yield Dividend Stocks I Plan to Buy in March for More Passive Income

3 Top High-Yield Dividend Stocks I Plan to Buy in March for More Passive Income

Generating passive income is a core aspect of my financial strategy. My goal is to eventually produce enough recurring investment income to cover my basic living expenses.

Fool | 9 months ago
3 Dividend Stocks That Are No-Brainer Buys Right Now

3 Dividend Stocks That Are No-Brainer Buys Right Now

It can be difficult to decide which dividend stocks to buy. After all, more than 5,700 of them trade on U.S. stock exchanges.

Fool | 9 months ago
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

Zacks | 9 months ago
Johnson & Johnson (JNJ) Could Be a Great Choice

Johnson & Johnson (JNJ) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?

Zacks | 9 months ago
Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note

Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note

In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $166.09, denoting a +1.44% change from the preceding trading day.

Zacks | 9 months ago
J&J sues Samsung Bioepis over contract breach for Stelara biosimilar

J&J sues Samsung Bioepis over contract breach for Stelara biosimilar

Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the drugmaker over the launch of a biosimilar to Stelara, J&J's autoimmune drug.

Reuters | 9 months ago
Loading...
Load More